CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Thalia Therapeutics PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Thalia Therapeutics PLC
C/O ARCH LAW HUCKLETREE BISHOPSGATE
8 BISHOPSGATE
Phone: +44 1332690061p:+44 1332690061 LONDON, EC2N 4BQ  United Kingdom Ticker: THATTHAT
Business Summary
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8741 Management services
5074 Plumbing and heating equipment and supplies (hydronics)
7372 Prepackaged software
8731 Commercial physical and biological research
5012 Automobiles and other motor vehicles
3571 Electronic computers
7379 Computer related services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board ChristopherBritten 8/1/2023 5/20/2019
Chief Executive Officer David H.Solomon 66 2/24/2026 2/24/2026
Executive Director Luke S.Cairns 44 7/15/2020 10/14/2015
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Nanogenics Ltd 2 Woodberry Grove London England United Kingdom

Business Names
Business Name
N4P
Nanogenics Ltd
ONZ
THAT

General Information
Number of Employees: 4 (As of 12/31/2024)
Outstanding Shares: 832,280,349 (As of 6/30/2025)
Shareholders: 2,752
Stock Exchange: LON
Fax Number: +44 1279821300


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 24, 2026